TrialAnnals of oncology : official journal of the European Society for Medical Oncology2021

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.

L Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.